Literature DB >> 11041017

Scintigraphic detection of multidrug resistance in cancer.

S Del Vecchio1, A Ciarmiello, M Salvatore.   

Abstract

One of the most extensively studied mechanisms of drug resistance involves the drug efflux pump P-glycoprotein (Pgp). The availability of radiolabeled substrates of Pgp such as 99mTc-MIBI and analogous 99mTc-labeled agents allows the clinical assessment of Pgp function in cancer patients. The consistency of the results from different institutions and trials strongly support the clinical application of this imaging technique for individual tailoring of chemotherapeutic regimens and for designing clinical trials with Pgp modulators.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11041017     DOI： 10.1089/cbr.2000.15.327

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN： 1084-9785            Impact factor:   3.099


  9 in total

1.  Single-photon-emission computed tomography (SPECT) with 99 technetium sestamibi in the diagnosis of small breast cancer and axillary node involvement.

Authors:  Hans Jacobsson
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

2.  Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody.

Authors:  Julliëtte E M van Eerd; Lioe-Fee de Geus-Oei; Wim J G Oyen; Frans H M Corstens; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-11       Impact factor: 9.236

3.  To use MIBI or not to use MIBI? That is the question when assessing tumour cells.

Authors:  Jean-Luc Moretti; Nathalie Hauet; Meltem Caglar; Olivier Rebillard; Zeynep Burak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07       Impact factor: 9.236

4.  Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin.

Authors:  Zhonglin Liu; Gail D Stevenson; Harrison H Barrett; Lars R Furenlid; Donald W Wilson; George A Kastis; Michael Bettan; James M Woolfenden
Journal:  Nucl Med Biol       Date:  2005-08       Impact factor: 2.408

5.  Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines.

Authors:  Luigi Aloj; Antonella Zannetti; Corradina Caracó; Silvana Del Vecchio; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-10       Impact factor: 9.236

6.  Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma.

Authors:  Silvana Del Vecchio; Antonella Zannetti; Luigi Aloj; Corradina Caracò; Andrea Ciarmiello; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-30       Impact factor: 9.236

7.  Predicting early chemotherapy response with technetium-99m methoxyisobutylisonitrile SPECT/CT in advanced non-small cell lung cancer.

Authors:  Tzu-I J Yang; Tjeerd S Aukema; Harm van Tinteren; Sjaak Burgers; Renato Valdés Olmos; Marcel Verheij
Journal:  Mol Imaging Biol       Date:  2009-09-12       Impact factor: 3.488

8.  Imaging recognition of multidrug resistance in human breast tumors using 99mTc-labeled monocationic agents and a high-resolution stationary SPECT system.

Authors:  Zhonglin Liu; Gail D Stevenson; Harrison H Barrett; George A Kastis; Michael Bettan; Lars R Furenlid; Donald W Wilson; James M Woolfenden
Journal:  Nucl Med Biol       Date:  2004-01       Impact factor: 2.408

9.  Influence of multidrug resistance on (18)F-FCH cellular uptake in a glioblastoma model.

Authors:  Claire Vanpouille; Nathalie Le Jeune; David Kryza; Anthony Clotagatide; Marc Janier; Francis Dubois; Nathalie Perek
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-20       Impact factor: 9.236
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.